Zhengye Biotechnology Holding (ZYBT) Work In Process (2023 - 2025)

Zhengye Biotechnology Holding (ZYBT) has reported Work In Process for 3 consecutive years, with $2.5 million the latest figure, recorded in Q4 2025.

• Quarterly Work In Process fell 45.8% year-over-year to $2.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.5 million (down 45.8% YoY) and the FY2025 annual result came in at $2.5 million, down 44.15% from the prior year.
• Work In Process retreated to $2.5 million in Q4 2025 per ZYBT's latest filing, from $4.6 million in the prior quarter.
• Over the last five years, Work In Process for ZYBT reached as high as $4.7 million in Q4 2023 and fell as low as $2.5 million in Q4 2025.
• A 3-year average of $3.9 million and a median of $4.6 million in 2024 frame the typical range for Work In Process.
• Annual changes were most pronounced in 2024 — Work In Process declined 1.31% — and 2025, when it tumbled 45.8%.
• Year by year, Work In Process stood at $4.7 million in 2023, then fell by 1.31% to $4.6 million in 2024, then slumped by 45.8% to $2.5 million in 2025.
• According to Business Quant data, Work In Process over the past three periods registered $2.5 million, $4.6 million, and $4.7 million for Q4 2025, Q4 2024, and Q4 2023 respectively.